Roche bid to retool arthritis drug for Covid-19 fails
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Wednesday
February 01, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
WEDNESDAY, FEBRUARY 01, 2023
Roche bid to retool arthritis drug for Covid-19 fails

Coronavirus chronicle

Reuters
29 July, 2020, 04:00 pm
Last modified: 29 July, 2020, 04:04 pm

Related News

  • Roche keen on serving more cancer and rare disease patients in Bangladesh  
  • Roche develops test kits to detect monkeypox virus
  • Life-saving Covid drug identified
  • US FDA lifts clinical hold on Inovio's Covid-19 vaccine trial
  • India's Everest Organics starts making ingredient for Merck's Covid-19 pill

Roche bid to retool arthritis drug for Covid-19 fails

Roche launched the 330-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic

Reuters
29 July, 2020, 04:00 pm
Last modified: 29 July, 2020, 04:04 pm
FILE PHOTO: Workers clean the windows of a building of Roche in Rotkreuz May 27, 2020. REUTERS/Arnd Wiegmann
FILE PHOTO: Workers clean the windows of a building of Roche in Rotkreuz May 27, 2020. REUTERS/Arnd Wiegmann

Roche's attempt to retool its rheumatoid arthritis drug Actemra/RoActemra to treat patients hospitalised with severe Covid-19-related pneumonia has failed in a late-stage trial, the Swiss company said on Wednesday.

Roche launched the 330-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic.

The "COVACTA trial did not meet its primary end-point of improved clinical status in patients with Covid-19 associated pneumonia, or the key secondary end-point of reduced patient mortality," Roche said.

The news follows an Italian study that showed the drug failed to help patients with early-stage Covid-19 pneumonia.

Roche shares were little changed.

"For Covid-19 patients in need of an effective treatment, today's news is disappointing. From an investment perspective, we never assumed a pandemic-driven long-term increase of Actemra revenues," Bank Vontobel analysts said.

Pharmaceutical companies have been racing to develop treatments against the Covid-19 pandemic that has claimed nearly 660,000 lives and crippled economies.

Around 150 companies are working on vaccines, although their first use cannot be expected until early 2021, the World Health Organization said last week.

Companies, meanwhile, have been trying to find ways to use existing drugs to treat Covid-19 patients.

India's Glenmark Pharmaceuticals Ltd for example, has been trialling its anti-flu drug favipiravir on patients with mild to moderate infections.

Roche is also testing if Actemra mixed with Gilead Sciences Inc's anti-viral treatment remdesivir works better against severe Covid-19 pneumonia than remdesivir or Actemra alone.

So far, remdesivir has been shown to help speed up recovery for Covid-19 patients, while the older generic steroid dexamethasone in a British-led trial reduced death rates by around a third among those with the most severe infections.

Roche said the Gilead collaboration was ongoing and it would continue to examine how Actemra could be used to treat Covid-19-related pneumonia. But it would not be applying for regulatory approval for use of the drug on its own against the condition.

The European Commission had struck a deal with Roche to secure supplies of RoActemra, but it was too early to comment on the commercial impact on the negative results of the COVACTA trial, a Roche spokesman said. 

The Commission was not immediately available to comment.

In the COVACTA trial, there was no difference in mortality rates after four weeks between patients who took Actemra/RoActemra and those who did not.

Although the drug reduced the time it took to discharge patients by an average of eight days, this was not considered significant as the main goal was not met.

"People around the world are waiting for further effective treatment options for Covid-19 and we are disappointed that COVACTA did not demonstrate a benefit for patients in either clinical status or mortality at week four," Levi Garraway, Roche's chief medical officer, said.

"We will continue to generate evidence to provide a more complete understanding of Actemra/RoActemra in Covid-19 associated pneumonia."

Roche / Covid-19 Drug

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Mugging rife in Tejgaon, murder in Wari
    Mugging rife in Tejgaon, murder in Wari
  • Will reform pledges to IMF work this time?
    Will reform pledges to IMF work this time?
  • Infographic: TBS
    How to redirect inward remittances to formal channels

MOST VIEWED

  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot

Related News

  • Roche keen on serving more cancer and rare disease patients in Bangladesh  
  • Roche develops test kits to detect monkeypox virus
  • Life-saving Covid drug identified
  • US FDA lifts clinical hold on Inovio's Covid-19 vaccine trial
  • India's Everest Organics starts making ingredient for Merck's Covid-19 pill

Features

An elderly couple's lonely battle to save Dhaka's trees

An elderly couple's lonely battle to save Dhaka's trees

5h | Panorama
Infographic: TBS

How to redirect inward remittances to formal channels

6h | Panorama
Photo: Bloomberg

How the 'madoffs of Manhattan' can unravel Gautam Adani's empire

5h | Panorama
Photo: Collected

Tips to incorporate sustainable construction

1d | Habitat

More Videos from TBS

Alka Yagnik guinness world record

Alka Yagnik guinness world record

3h | TBS Entertainment
Interest rate should be left to market

Interest rate should be left to market

3h | TBS Round Table
Adani’s shares fell sharply after allegation

Adani’s shares fell sharply after allegation

19h | TBS World
Why Messi was blocked on Instagram?

Why Messi was blocked on Instagram?

18h | TBS SPORTS

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
Photo: Saqlain Rizve
Bangladesh

Bangladeshi university students identified as problematic users of Facebook, internet: Study

4
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

5
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

6
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]